000 01319 a2200421 4500
005 20250518041803.0
264 0 _c20191003
008 201910s 0 0 eng d
022 _a1179-2019
024 7 _a10.1007/s40272-019-00337-7
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aBevacqua, M
245 0 0 _aOff-Label Use of Sirolimus and Everolimus in a Pediatric Center: A Case Series and Review of the Literature.
_h[electronic resource]
260 _bPaediatric drugs
_cJun 2019
300 _a185-193 p.
_bdigital
500 _aPublication Type: Case Reports; Journal Article; Review
650 0 4 _aAdolescent
650 0 4 _aAntineoplastic Agents
_xpharmacology
650 0 4 _aChild
650 0 4 _aChild, Preschool
650 0 4 _aEverolimus
_xpharmacology
650 0 4 _aFemale
650 0 4 _aHumans
650 0 4 _aInfant
650 0 4 _aMale
650 0 4 _aOff-Label Use
_xstandards
650 0 4 _aSirolimus
_xpharmacology
700 1 _aBaldo, F
700 1 _aPastore, S
700 1 _aValencic, E
700 1 _aTommasini, Alberto
700 1 _aMaestro, A
700 1 _aRabusin, M
700 1 _aArbo, A
700 1 _aBarbi, E
773 0 _tPaediatric drugs
_gvol. 21
_gno. 3
_gp. 185-193
856 4 0 _uhttps://doi.org/10.1007/s40272-019-00337-7
_zAvailable from publisher's website
999 _c29724910
_d29724910